More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests SOUTH SAN FRANCISCO, ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests “The breadth of data at ASCO GU ...

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests Veracyte, Inc. (Nasdaq: VCYT), a ...

Profiling BCRAness phenotype in public prostate cancer datasets without homologous repair gene mutations. Cardiometabolic health’s influence on outcomes in men with localized high-risk prostate cancer ...

Prostate cancer is the most commonly diagnosed cancer among men in the United Kingdom. Because of this, many men look for ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...